255 related articles for article (PubMed ID: 12654259)
1. Angiogenesis and apoptosis.
Folkman J
Semin Cancer Biol; 2003 Apr; 13(2):159-67. PubMed ID: 12654259
[TBL] [Abstract][Full Text] [Related]
2. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.
Kerbel RS; Viloria-Petit A; Klement G; Rak J
Eur J Cancer; 2000 Jun; 36(10):1248-57. PubMed ID: 10882863
[TBL] [Abstract][Full Text] [Related]
3. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
Folkins C; Man S; Xu P; Shaked Y; Hicklin DJ; Kerbel RS
Cancer Res; 2007 Apr; 67(8):3560-4. PubMed ID: 17440065
[TBL] [Abstract][Full Text] [Related]
4. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis research: from laboratory to clinic.
Folkman J
Forum (Genova); 1999; 9(3 Suppl 3):59-62. PubMed ID: 10607848
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
Browder T; Butterfield CE; Kräling BM; Shi B; Marshall B; O'Reilly MS; Folkman J
Cancer Res; 2000 Apr; 60(7):1878-86. PubMed ID: 10766175
[TBL] [Abstract][Full Text] [Related]
7. Schedule-Dependent Antiangiogenic and Cytotoxic Effects of Chemotherapy on Vascular Endothelial and Retinoblastoma Cells.
Winter U; Mena HA; Negrotto S; Arana E; Pascual-Pasto G; Laurent V; Suñol M; Chantada GL; Carcaboso AM; Schaiquevich P
PLoS One; 2016; 11(7):e0160094. PubMed ID: 27467588
[TBL] [Abstract][Full Text] [Related]
8. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
9. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
Li D; Williams JI; Pietras RJ
Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
[TBL] [Abstract][Full Text] [Related]
11. Endothelial Side Population Cells Contribute to Tumor Angiogenesis and Antiangiogenic Drug Resistance.
Naito H; Wakabayashi T; Kidoya H; Muramatsu F; Takara K; Eino D; Yamane K; Iba T; Takakura N
Cancer Res; 2016 Jun; 76(11):3200-10. PubMed ID: 27197162
[TBL] [Abstract][Full Text] [Related]
12. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells.
Xiong YQ; Sun HC; Zhang W; Zhu XD; Zhuang PY; Zhang JB; Wang L; Wu WZ; Qin LX; Tang ZY
Clin Cancer Res; 2009 Aug; 15(15):4838-46. PubMed ID: 19638466
[TBL] [Abstract][Full Text] [Related]
13. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
[TBL] [Abstract][Full Text] [Related]
14. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
16. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis: new targets for the development of anticancer chemotherapies.
Gourley M; Williamson JS
Curr Pharm Des; 2000 Mar; 6(4):417-39. PubMed ID: 10788590
[TBL] [Abstract][Full Text] [Related]
18. Antineovascular therapy, a novel antiangiogenic approach.
Shimizu K; Asai T; Oku N
Expert Opin Ther Targets; 2005 Feb; 9(1):63-76. PubMed ID: 15757482
[TBL] [Abstract][Full Text] [Related]
19. Overview of angiogenesis: Biologic implications for antiangiogenic therapy.
Ellis LM; Liu W; Ahmad SA; Fan F; Jung YD; Shaheen RM; Reinmuth N
Semin Oncol; 2001 Oct; 28(5 Suppl 16):94-104. PubMed ID: 11706401
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of angiogenesis in cancers.
Pang RW; Poon RT
Vasc Health Risk Manag; 2006; 2(2):97-108. PubMed ID: 17319453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
